Michael Wyand

Dr. Wyand is a biopharmaceutical executive with over twenty-five years experience in managing and building successful product and service oriented life science companies.

An accomplished leader, Dr. Wyand has substantial experience managing R&D and as a corporate officer responsible for communicating corporate strategy and value propositions to company directors, external investors and partners. Dr. Wyand was President/COO of Epirus Biopharmaceuticals after starting as CTO from 2012 to 2016. At Epirus, Dr. Wyand managed a portfolio of biosimilar monoclonal antibodies at both development and commercial stages with global partners in Europe and Asia.

Prior to Epirus Dr. Wyand headed R&D at Percivia, a J&J/DSM joint venture; BioAssets Development, acquired by Cephalon for $120M; and Therion Biologics, a pioneering private-equity-financed, cancer vaccine company. At Therion, Dr. Wyand lead the development of PROSTVAC, a pox-virus based immunotherapeutic vaccine for prostate cancer, licensed by Bristol-Myers Squibb Company for $975M in 2015 and managed the design/build of a cGMP manufacturing plant in Cambridge, MA.

Dr. Wyand started his career at Mason Laboratory a wholly owned subsidiary of Genzyme Transgenics where he was President and CSO and served as Principal Investigator on a $7M NIAID AIDS vaccine contract. Dr. Wyand trained in comparative pathology at Harvard Medical School, received his DVM from Purdue University and his PhD in Pathology from the University of Connecticut. He received a BS in Biology from the University of Connecticut where he graduated with honors as a University Scholar.